Skip to main content
Portfolio
TrendingMidtermsElectionsPoliticsSportsCultureCryptoCommoditiesClimateEconomicsMentions

Finance

Tech & Science
PredictLive165AccountSocial
MARKETSINVESTLIVE165

Biotech

Product
Kalshi ProInvestMarketsIncentive programSmall business hedgingInstitutionsAPI & developers
Company
AboutKalshi ResearchBlogCareersPolicy CenterBrand Kit
Help
Help CenterFAQPrediction marketsFee scheduleTrading hoursRegulatoryTrust Center

© 2026 Kalshi Inc. · All rights reserved
PrivacyData Terms of ServiceTrading ProhibitionsFAQ for Finance Professionals
Trading on Kalshi involves risk and may not be appropriate for all. Members risk losing their cost to enter any transaction, including fees. You should carefully consider whether trading on Kalshi is appropriate for you in light of your investment experience and financial resources. Any trading decisions you make are solely your responsibility and at your own risk. Information is provided for convenience only on an "AS IS" basis. Past performance is not necessarily indicative of future results. Kalshi is subject to U.S. regulatory oversight by the CFTC.
All markets (708)
15 min (10)
Hourly (8)
Daily (26)
Weekly (14)
Monthly (49)
Annual (20)

Public Companies Hub
Indices
Foreign Exchange
Interest Rates
Company metrics
Company news
Industries
Biotech
Advertising Spend
Real Estate
Sector Trends
Match Ups
Black Friday

Financials odds and guides

IPO odds for every company

FDA decision: Saroglitazar by Zydus Therapeutics (this year)

Yes
1.26x
No
4.13x
$1,712 vol

FDA decision: BBP-418 by Ml Bio Solutions Inc. (this year)

Yes
1.08x
No
6.74x
$944 vol

FDA decision: Venglustat by Sanofi (this year)

Yes
1.16x
No
4.31x
$1,011 vol

FDA decision: Vamikibart by Genentech (on or before July 31, 2027)

Yes
1.44x
No
2.34x
$42 vol

FDA decision: Ulixacaltamide by Praxis Precision Medicines (on or before January 29, 2027)

Yes
1.28x
No
2.98x
$12 vol

FDA decision: Tozorakimab by AstraZeneca (on or before March 31, 2027)

Yes
1.23x
No
3.40x
$308 vol

FDA decision: Ralinepag by United Therapeutics (on or before June 24, 2027)

Yes
1.19x
No
3.80x
$41 vol

FDA decision: Lorundrostat by Mineralys Therapeutics (on or before December 22, 2026)

Yes
1.14x
No
4.51x
$70 vol

KT-621 Week 16 EASI-75 advantage over placebo

Above 20.0 pp
1.01x
Above 25.0 pp
1.01x
$0 vol

FDA decision: Anitocabtagene Autoleucel (anito-cel) by Gilead Sciences (this year)

Yes
1.12x
No
7.85x
$4,230 vol